Amer Zeidan, Professor of Medicine, Chief of Hematologic Malignancies, Director of Heme Clinical Research at Yale University, shared a post on LinkedIn:
“My editorial for Blood Cancers Today on how two important phase 2 clinical trials (ASCERTAIN V and PARADIGM) are opening the door to a major change of how we treat acute myeloid leukemia.”
Other articles featuring Dr. Zeidan on OncoDaily.